<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949361</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2017-01742</org_study_id>
    <nct_id>NCT03949361</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Long-term Administration: Effect on Cold Induced Energy Expenditure and Resting Metabolic Rate</brief_title>
  <acronym>GLACIER</acronym>
  <official_title>Glucocorticoid Long-term Administration: Effect on Cold Induced Energy Expenditure and Resting Metabolic Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETH Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate whether treatment with glucocorticoids leads to a&#xD;
      change in heat production of the human body at mild cold conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brown adipose tissue (BAT) is a thermogenic tissue that can convert chemical energy directly&#xD;
      into heat due to the expression of uncoupling protein 1 (UCP1) protein. Data from preclinical&#xD;
      studies shows that glucocorticoids (GCs) inhibit the function of BAT. In clinical practice&#xD;
      GCs are often administered due tue their antiinflammatory properties making the investigation&#xD;
      of short term (e.g. one week) and long therm (several months) effects practically relevant.&#xD;
      This study's objective is to evaluate the effect of glucocorticoid treatment on cold induced&#xD;
      thermogenesis (CIT) in humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cold-induced thermogenesis (CIT) under glucocorticoids</measure>
    <time_frame>Change from glucocortoid start to +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of CIT change off-glucocorticoids with warm ischemia time (WIT) on-glucocorticoids by using indirect calorimetry. Comparing two Groups (Observation group A and B) we will address the CIT change from glucocorticoid start to 4-8 weeks into treatment (group A) and the CIT change from glucocorticoid therapy to weaning off upon more than 3 months after glucocorticoid withdrawal (group B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate (RMR)</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of RMR of patients starting GCs or patients stopping GCs, measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of body composition concerning muscle mass and fat mass, determined by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold stimulated glucose uptake into supraclavicular BAT</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Determination of 'standardized uptake value' (SUV) mean in two volumes of interest on the supraclavicular adipose tissue, after PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV max in supraclavicular adipose tissue depot</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Determination of SUV max in the supraclavicular adipose tissue, after positron emission tomography (PET)-CT</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Thermoregulation Impairment</condition>
  <arm_group>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <description>Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
    <description>Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>Resting energy expenditure</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin Temperature</intervention_name>
    <description>Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual energy X-ray Absorptiometry (DXA)</intervention_name>
    <description>Body composition</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG-PET</intervention_name>
    <description>Dynamic PET scanning of the neck-region</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Capillary glucose</intervention_name>
    <description>Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biopsy of supraclavicular adipose tissue (optional)</intervention_name>
    <description>Ultrasound guided biopsy of the supraclavicular adipose tissue</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma Optional biopsy of supraclavicular BAT&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited via the outpatient clinics (endocrinology, rheumathology,&#xD;
        ophthalmology, gastroenterology etc.) of the Basel University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned therapy with at least 7.5 mg prednisone equivalent per day or higher for more&#xD;
             than 28 days (group A)&#xD;
&#xD;
          -  Planned weaning off glucocorticoid therapy which lasted al least 28 days with a dosage&#xD;
             of at least 7.5 mg prednisone (group B)&#xD;
&#xD;
          -  BMI 19-30 kg/m2&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient thyroid hormone substitution in case of hypothyroidism&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (HbA1c &gt;7.5%)&#xD;
&#xD;
          -  Severe concomitant diseases: chronic heart failure, liver cirrhosis, kidney failure,&#xD;
             active cancer&#xD;
&#xD;
          -  Known hypersensitivity to cold, e.g. primary or secondary Raynaud's Syndrome&#xD;
&#xD;
          -  Known or suspected non-compliance&#xD;
&#xD;
          -  Abuse of alcohol or illicit drugs&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc of the participant&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
&#xD;
          -  Enrolment into another study using ionizing radiation within the previous 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Matthias, PD Dr. med</last_name>
    <role>Study Director</role>
    <affiliation>Klinik Endokrinologie, Diabetes und Metabolismus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Endocrinology</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucocorticoids</keyword>
  <keyword>Brown Adipose tissue</keyword>
  <keyword>Cold Induced Thermogenesis</keyword>
  <keyword>Resting Metabolic Rate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

